ALKS vs PEAK
Alkermes Plc (ALKS) versus PEAK (PEAK) — a side-by-side from cached financials, not a winner call.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
PEAK (PEAK) common stock.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
PEAK does not have a complete income-statement cache yet.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Not investment advice. Open the ALKS and PEAK stock pages for the full models.
Not investment advice.